Cutaneous Amebiasis (ICD-11: 1A36.12) - Complete Coding Guide

1. Introduction

Cutaneous amebiasis is a rare, yet clinically significant manifestation of extraintestinal infections caused by Entamoeba histolytica. This condition represents an atypical form of amebiasis presentation, occurring when the protozoan invades the skin and subcutaneous tissues, usually through direct extension from adjacent lesions or, less commonly, through hematogenous dissemination.

The clinical importance of cutaneous amebiasis lies in its presentation, which is frequently confused with other ulcerative dermatoses, leading to diagnostic delays and inadequate treatment. Although considered an uncommon manifestation of E. histolytica infection, its occurrence is associated with specific contexts that include patients with untreated intestinal amebiasis, immunocompromised individuals, and situations where there is direct contamination of surgical or traumatic wounds with infected fecal material.

From an epidemiological perspective, cutaneous amebiasis is most frequently observed in tropical and subtropical regions with poor sanitary conditions, where intestinal amebiasis remains endemic. The cutaneous manifestation represents less than 1% of all cases of extraintestinal amebiasis, being surpassed in frequency by hepatic and pulmonary abscesses.

Correct coding of cutaneous amebiasis is critical for multiple reasons. First, it enables appropriate epidemiological tracking of this rare manifestation, contributing to the understanding of its actual prevalence and patterns of geographic distribution. Second, it facilitates communication among healthcare professionals, ensuring that the specific nature of the infection is clearly documented. Third, it directly impacts therapeutic planning, since cutaneous amebiasis requires systemic treatment with tissue amebicides, unlike other dermatoses that may be treated topically only. Finally, accurate documentation is essential for reimbursement purposes, clinical research, and public health surveillance.

2. Correct ICD-11 Code

Code: 1A36.12

Description: Cutaneous amebiasis

Parent category: 1A36.1 - Extraintestinal infections by Entamoeba

The ICD-11 classification organized the manifestations of amebiasis in a hierarchical and more specific manner than its predecessor. The code 1A36.12 is situated within the larger structure of infectious diseases caused by protozoa, specifically under extraintestinal infections by Entamoeba.

This categorization reflects the current understanding that cutaneous amebiasis is not a primary skin infection, but rather an extension or complication of systemic infection by E. histolytica. The position of the code within the ICD-11 hierarchy emphasizes that this is an extraintestinal manifestation, clearly differentiating it from intestinal amebiasis (amebic colitis), which has its own category of codes.

The code 1A36.12 is specific and does not have additional subcategories, which means that all forms of cutaneous involvement by E. histolytica should be coded under this unique identifier. This includes perianal ulcerations, cutaneous lesions from direct extension of visceral abscesses that fistulized through the abdominal wall, and rare cases of cutaneous lesions from hematogenous dissemination.

The structure of the code allows for easy identification: the prefix "1A" indicates infectious or parasitic diseases, "36" specifies infections by Entamoeba, ".1" denotes extraintestinal manifestations, and ".12" specifically identifies cutaneous involvement. This logical organization facilitates both coding and data retrieval for epidemiological analyses.

3. When to Use This Code

The code 1A36.12 should be used in specific clinical scenarios where there is confirmed or strongly suggestive evidence of cutaneous involvement by Entamoeba histolytica. Below, we present detailed practical situations:

Scenario 1: Perianal ulceration in patient with amebic colitis

A patient presents with a history of chronic bloody diarrhea with confirmed diagnosis of amebic colitis by colonoscopy and identification of E. histolytica trophozoites in stool samples. Subsequently, the patient develops painful ulcerative lesions in the perianal and perineal region, with raised borders and central necrosis. Skin biopsy reveals amebic trophozoites in tissues. This is the classic scenario for use of code 1A36.12, representing direct extension of intestinal infection to adjacent skin.

Scenario 2: Cutaneous fistula secondary to amebic liver abscess

Patient with a large amebic liver abscess in the right lobe of the liver that progresses with spontaneous drainage through the abdominal wall, creating a hepatocutaneous fistula. The area around the fistulous opening develops ulceration with necrotic borders, and microscopic examination of the drained material identifies E. histolytica trophozoites. In this case, in addition to the code for liver abscess (1A36.10), code 1A36.12 should be added to document secondary cutaneous involvement.

Scenario 3: Post-operative cutaneous lesion with contamination

Patient who underwent abdominal surgery for resection of intestinal segment affected by invasive amebiasis. In the postoperative period, the surgical wound develops partial dehiscence with ulcer formation displaying typical characteristics: excavated borders, necrotic base, serosanguineous discharge, and fetid odor. Culture of wound material and histopathological examination confirm the presence of E. histolytica. Code 1A36.12 is appropriate for documenting this specific complication.

Scenario 4: Genital lesion in context of sexual transmission

Although extremely rare, there are reports of ulcerative genital lesions caused by E. histolytica in the context of oroanal sexual practices. A patient presents with painful genital ulcers unresponsive to conventional antibiotic treatment for common sexually transmitted infections. Detailed investigation, including biopsy and molecular techniques, identifies E. histolytica as the etiologic agent. Code 1A36.12 should be used in this uncommon situation.

Scenario 5: Cutaneous lesion in immunocompromised patient

Patient living with HIV at an advanced stage or on immunosuppressive therapy develops ulcerative cutaneous lesions in sites not contiguous to the gastrointestinal tract. Investigation reveals hematogenous dissemination of E. histolytica with cutaneous implantation. Although rare, this presentation requires code 1A36.12, and additional codes may be necessary to document the underlying immunodeficiency status.

Scenario 6: Ameboma with cutaneous extension

Patient with ameboma (granulomatous mass caused by E. histolytica) in the intestinal wall that extends through the abdominal wall, creating a palpable mass with overlying cutaneous ulceration. Biopsy confirms the amebic nature of the lesion. This scenario justifies the use of code 1A36.12 in conjunction with appropriate codes for the intestinal lesion.

4. When NOT to Use This Code

It is fundamental to recognize situations where code 1A36.12 is not appropriate, avoiding coding errors that may compromise the accuracy of medical records and epidemiological data.

Isolated intestinal amebiasis: When the patient presents only gastrointestinal manifestations of amebiasis (diarrhea, colitis, dysentery) without any cutaneous involvement, code 1A36.12 should not be used. In these cases, specific codes for intestinal amebiasis are appropriate.

Hepatic or pulmonary abscess without cutaneous involvement: Patients with amebic abscesses in internal organs who have not developed extension or fistulization to the skin should be coded only with the specific codes for these locations (1A36.10 for liver, 1A36.11 for lung), without adding code 1A36.12.

Other ulcerative dermatoses: Cutaneous ulcers caused by other infectious agents (bacterial, fungal, viral, or other parasites) should not be coded as cutaneous amebiasis, even if the patient has a history of prior intestinal amebiasis. The diagnosis of cutaneous amebiasis requires specific confirmation of the presence of E. histolytica in cutaneous tissues.

Nonspecific cutaneous lesions in asymptomatic carriers: Individuals who are asymptomatic carriers of E. histolytica (or E. dispar) in the intestinal tract but present with unrelated cutaneous lesions should not have these lesions coded as 1A36.12 unless there is direct evidence that the lesions are caused by the protozoan.

Cutaneous reactions to antiamebic treatment: Skin rashes, urticaria, or other dermatological reactions related to the use of medications for treating intestinal amebiasis are not cutaneous amebiasis and should be coded as adverse drug reactions.

Scars from previous amebic lesions: After successful treatment of cutaneous amebiasis, residual scars should not continue to be coded as 1A36.12. The code is reserved for active infection.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

The diagnosis of cutaneous amebiasis requires a systematic and multifaceted approach. Initially, the presence of cutaneous lesions with suggestive characteristics must be established: ulcers with raised and excavated borders, necrotic base, rapid progression, and location frequently in areas of contiguity with the gastrointestinal tract or along drainage tracts of visceral abscesses.

Ideal diagnostic confirmation includes direct identification of E. histolytica trophozoites through microscopic examination of scrapings or biopsy of the ulcer borders. The biopsy should show tissue necrosis with mixed inflammatory infiltrate and, crucially, the presence of trophozoites with typical morphological characteristics (nucleus with peripheral chromatin and small central karyosome).

Complementary methods include direct immunofluorescence techniques, PCR (polymerase chain reaction) for detection of E. histolytica-specific DNA, and serological tests that detect anti-E. histolytica antibodies. It is important to note that serology may be positive in extraintestinal infections but does not distinguish between active infection and prior exposure.

Clinical history is fundamental: investigating travel to endemic areas, sanitary conditions, history of bloody diarrhea, recent abdominal surgical procedures, and the patient's immunological status. The presence of concomitant or prior intestinal amebiasis significantly strengthens the diagnostic suspicion.

Step 2: Verify specifiers

Although code 1A36.12 does not have formal subcategories in ICD-11, clinical documentation should include important specifiers that characterize the individual case presentation. These include the precise anatomical location of lesions (perianal, abdominal, genital, etc.), the extent of cutaneous involvement (number and size of lesions), and the severity of presentation.

Documenting whether cutaneous amebiasis is primary (extremely rare) or secondary to another amebic manifestation is clinically relevant. In most cases, it is direct extension of amebic colitis or fistulization of a visceral abscess. This information contextualizes the coding and may justify the use of multiple codes.

The duration of symptoms should be recorded, distinguishing between acute presentations (days to weeks) and chronic presentations (months). The response to previous treatments, especially if conventional antibiotics were used without success, is also valuable information that supports the diagnosis.

Associated complications, such as secondary bacterial infection, extensive cellulitis, or formation of complex fistulas, should be documented and may require additional codes to fully capture the complexity of the clinical picture.

Step 3: Differentiate from other codes

Differentiation from 1A36.10 (Amebic liver abscess): Amebic hepatic abscess presents with fever, right hypochondrial pain, painful hepatomegaly, and imaging findings showing cystic hepatic lesion. Code 1A36.10 is used when involvement is restricted to the liver. If there is fistulization of the abscess through the abdominal wall with cutaneous involvement, both codes (1A36.10 and 1A36.12) should be used, with the hepatic code as the principal diagnosis and the cutaneous code as a secondary complication.

Differentiation from 1A36.11 (Amebic lung abscess): Pulmonary involvement is characterized by cough, chest pain, dyspnea, and pulmonary consolidation on imaging studies. Code 1A36.11 is specific for pulmonary lesions. Rarely, an amebic lung abscess may drain through the chest wall (empyema necessitatis), creating secondary cutaneous involvement. In this exceptional situation, both codes would be appropriate, with the pulmonary code as principal.

Differentiation from other parasitic cutaneous infections: Cutaneous leishmaniasis, myiasis, and other cutaneous parasitoses may present with similar ulcers. Differentiation is based on specific identification of the etiological agent through microscopic, cultural, or molecular methods. Epidemiological history and the presence of concomitant intestinal manifestations favor amebiasis.

Step 4: Necessary documentation

Adequate documentation to justify code 1A36.12 should include a comprehensive checklist of information:

Detailed description of lesions: precise anatomical location, number of lesions, dimensions, characteristics of borders and ulcer base, presence of discharge and its characteristics, perilesional inflammatory signs.

Results of diagnostic tests: microscopy report identifying E. histolytica trophozoites, biopsy results with histopathological description, PCR results if performed, serum antibody titers, stool examinations if performed.

Clinical context: history of gastrointestinal symptoms, recent travel, sanitary conditions of exposure, prior surgical procedures, immunological status, relevant comorbidities.

Temporal evolution: date of onset of cutaneous symptoms, disease progression, previous treatments attempted and their responses.

Therapeutic plan: amebicidal medication prescribed, planned dose and duration, need for surgical interventions or drainage procedures.

This complete documentation not only justifies the coding but also provides valuable information for continuity of care and for audit and research purposes.

6. Complete Practical Example

Clinical Case

A 42-year-old male patient, agricultural worker, presents to the dermatology service with a complaint of "non-healing wound" in the perianal region for three weeks. He reports that he initially noticed a small painful lesion near the anus, which progressively increased in size despite the use of antibiotic ointments prescribed at a previous visit.

On directed history, the patient mentions that approximately two months ago he had episodes of diarrhea with mucus and blood, which lasted about three weeks. He sought medical care at that time, received symptomatic and oral antibiotic treatment (unable to specify which), with partial improvement of the intestinal condition. He denies current fever but reports febrile episodes during the diarrhea period. He has no known comorbidities and denies use of immunosuppressive medications. He works in a rural area with poor sanitary conditions.

On dermatological physical examination, an ulcer is observed in the right perianal region, measuring approximately 4 x 3 cm, with raised, hardened, and well-demarcated borders. The ulcer base presents yellowish necrotic tissue with areas of granulation. There is scant serosanguineous discharge and characteristic foul odor. Palpation of the borders is extremely painful. There is no significant inguinal lymphadenopathy. The remainder of the physical examination is normal, without hepatomegaly or other relevant findings.

Given the atypical presentation and history of previous bloody diarrhea, complementary tests were requested. A biopsy of the ulcer border was performed, and histopathological examination revealed extensive tissue necrosis with mixed inflammatory infiltrate and, significantly, identification of structures compatible with trophozoites of Entamoeba histolytica. Special staining with PAS (periodic acid-Schiff) confirmed the presence of protozoa.

Parasitological stool examination was requested and identified cysts of E. histolytica in two of three samples analyzed. Serology for amebiasis showed elevated titers of anti-E. histolytica IgG antibodies, suggesting invasive infection. Abdominal ultrasound was performed to investigate possible hepatic abscess but revealed no significant abnormalities.

Step-by-Step Coding

Criteria analysis:

1. Presence of characteristic skin lesion: Perianal ulcer with raised borders, necrotic base, and progressive evolution - criterion met.

2. Etiological confirmation: Histopathological identification of E. histolytica trophozoites in skin biopsy - fundamental criterion met.

3. Compatible clinical context: History of previous bloody diarrhea (suggestive of amebic colitis), exposure to poor sanitary conditions, perianal location of the lesion (contiguous to the gastrointestinal tract) - supporting criteria met.

4. Exclusion of alternative diagnoses: Lack of response to conventional antibiotics, morphological characteristics not compatible with other common causes of perianal ulcers (sexually transmitted diseases, Crohn's disease, cutaneous tuberculosis).

Code selected: 1A36.12 - Cutaneous amebiasis

Complete justification:

Code 1A36.12 is most appropriate for this case because it precisely documents the cutaneous extraintestinal manifestation of Entamoeba histolytica infection. Histopathological confirmation of the presence of the protozoan in cutaneous tissues is the definitive criterion for this coding.

The lesion represents direct extension of intestinal infection (amebic colitis) to the perianal skin, one of the classic scenarios of cutaneous amebiasis. The anatomical location, morphological characteristics of the ulcer, and clinical history are entirely consistent with this diagnosis.

Complementary codes:

Although the primary code is 1A36.12, it is appropriate to consider additional codes to fully capture the clinical picture:

• Code for intestinal amebiasis (if there is evidence of concomitant active colitis)
• Code for local complications if present (such as secondary cellulitis)
• Z codes to document risk factors or occupational context, if relevant to the specific health system

Documented treatment plan:

The patient was started on systemic metronidazole treatment followed by a luminal agent (paromomycin or another luminal-acting amebicide), according to standard protocol for invasive amebiasis. Local wound care was instituted, and dermatological and infectious disease follow-up was scheduled. Documentation of the therapeutic plan reinforces the coding justification and allows for outcome tracking.

7. Related Codes and Differentiation

Within the Same Category

1A36.10: Amebic liver abscess

This code is used when there is abscess formation in the hepatic parenchyma caused by Entamoeba histolytica. The fundamental differentiation from 1A36.12 lies in the anatomical location of the extraintestinal manifestation.

When to use 1A36.10 vs. 1A36.12: Use 1A36.10 when the patient presents with fever, right hypochondrial pain, painful hepatomegaly, and imaging studies (ultrasound, computed tomography, or magnetic resonance imaging) demonstrating cystic lesion in the liver with abscess characteristics. Use 1A36.12 when there is confirmed cutaneous involvement, either isolated or in association with other manifestations.

Situation for combined use: In cases where an amebic liver abscess fistulizes through the abdominal wall, creating a hepatocutaneous communication with skin ulceration, both codes should be used. Code 1A36.10 would be the primary diagnosis (the origin of the problem), and 1A36.12 would be secondary (complication of the liver abscess).

1A36.11: Amebic lung abscess

This code documents pulmonary involvement by E. histolytica, usually resulting from direct extension of a liver abscess through the diaphragm or, rarely, from hematogenous dissemination.

When to use 1A36.11 vs. 1A36.12: Code 1A36.11 is appropriate when the patient presents with respiratory symptoms (cough, dyspnea, pleuritic chest pain), and thoracic imaging studies reveal consolidation or pulmonary abscess. Code 1A36.12 is used for cutaneous manifestations. The main difference lies in the affected organ.

Exceptional situation: In extremely rare cases of amebic empyema necessitatis (spontaneous drainage of pulmonary abscess through the thoracic wall), both 1A36.11 and 1A36.12 may be necessary to completely document the complex clinical presentation.

Differential Diagnoses

Cutaneous leishmaniasis: Presents with ulcers with raised borders and granular base, but microscopic identification reveals amastigotes of Leishmania (distinct intracellular structures) and not trophozoites of E. histolytica. Epidemiological history (exposure to phlebotomine sand flies) and absence of gastrointestinal symptoms aid in differentiation.

Cutaneous tuberculosis: May present with chronic ulcers, but generally with more verrucous or lupoid characteristics. Biopsy shows caseating granulomas and acid-fast bacilli, not protozoa. History of pulmonary tuberculosis or exposure to TB cases is common.

Perianal Crohn's disease: May cause perianal ulcers and fistulas, but the clinical context includes chronic inflammatory bowel disease, and biopsy shows non-caseating granulomatous inflammation without identifiable infectious organisms.

Squamous cell carcinoma: Malignant ulcers have harder and more irregular borders, and biopsy reveals neoplastic cells, not parasitic infection.

Bacterial infections (pyodermatitis, ecthyma): Bacterial ulcers generally respond to conventional antibiotics and culture identifies pathogenic bacteria, not protozoa.

Definitive differentiation in all these cases depends on specific identification of E. histolytica through microscopic, histopathological, or molecular methods in cutaneous lesions.

8. Differences with ICD-10

In the ICD-10 classification, cutaneous amebiasis was coded under A06.7 - Cutaneous amebiasis. The transition to ICD-11 brought significant changes in the organization and specificity of coding.

Main structural changes:

ICD-11 reorganized the extraintestinal manifestations of amebiasis under a specific parent category (1A36.1), creating a more logical and intuitive hierarchy. In ICD-10, code A06.7 was listed together with other amebic manifestations without such a clear hierarchical structure.

The new code 1A36.12 provides greater specificity through its numerical structure, facilitating the identification of the extraintestinal and cutaneous nature of the infection. The nomenclature is more descriptive and aligned with contemporary medical terminology.

Practical impact:

For healthcare professionals and coders, the transition requires familiarization with the new code structure. Health information systems need to be updated to adequately map the old code (A06.7) to the new one (1A36.12), ensuring continuity in epidemiological data and allowing time series analyses.

The greater specificity of ICD-11 potentially improves the accuracy of epidemiological surveillance data, allowing better tracking of this rare manifestation of amebiasis. The hierarchical structure facilitates queries of aggregated data on extraintestinal infections by Entamoeba as a group.

For billing and reimbursement purposes in health systems, the change may impact administrative processes, requiring updates to procedure tables and associated values. Clinical documentation must be sufficiently detailed to justify the specificity of the new code.

9. Frequently Asked Questions

1. How is the definitive diagnosis of cutaneous amebiasis made?

Definitive diagnosis requires identification of Entamoeba histolytica in cutaneous tissues. The most reliable method is biopsy of the ulcer border, with histopathological examination showing characteristic trophozoites. Direct microscopic examination of scrapings from the lesion borders can identify motile trophozoites, but is less sensitive. Molecular techniques such as PCR offer high sensitivity and specificity, differentiating E. histolytica from E. dispar (non-pathogenic). Serological tests detect anti-E. histolytica antibodies and are positive in most cases of invasive amebiasis, but do not distinguish active infection from prior exposure. The combination of characteristic clinical findings, appropriate epidemiological context, and laboratory confirmation provides the most robust diagnosis.

2. Is treatment available in public health systems?

Medications for treatment of cutaneous amebiasis, including metronidazole and other nitroimidazoles, are widely available in public health systems in many countries. These medications are considered essential by the World Health Organization and generally are part of basic medication lists. Complete treatment requires a tissue amebicide (such as metronidazole or tinidazole) followed by a luminal agent (such as paromomycin or iodoquinol) to eradicate intestinal cysts and prevent recurrence. Specific availability may vary among different health systems and geographic regions, but medications are relatively accessible and moderately priced. Local wound care, including cleaning and appropriate dressings, are important components of treatment and generally available in basic health services.

3. How long does treatment last and what is the prognosis?

Systemic treatment with metronidazole generally lasts 7 to 10 days, followed by a luminal agent for an additional 7 to 14 days. Healing of cutaneous lesions may take several weeks after initiation of treatment, depending on the initial extent of tissue damage. The prognosis is generally excellent with adequate and timely treatment. Most patients show significant improvement in symptoms within 3 to 5 days after starting amebicidal therapy. Complications are rare when treatment is instituted early, but diagnostic delays can result in extensive tissue destruction with disfiguring scars. Recurrences are uncommon if complete treatment (tissue and luminal) is administered appropriately. Regular clinical follow-up during and after treatment is important to monitor therapeutic response and detect complications early.

4. Can this code be used in medical certificates and legal documents?

Yes, code 1A36.12 can and should be used in official medical documentation, including certificates, medical reports, and legal documents when appropriate. Accurate coding is important for proper documentation of the medical condition, justification for work absence when necessary, and for insurance and health benefits purposes. In medical certificates, the code may be used accompanied by the description "cutaneous amebiasis" or simply "cutaneous parasitic infection" if greater discretion is desired, depending on local regulations regarding medical privacy. For legal documentation, the specificity of the code and detailed description of the condition are important. Healthcare professionals should be aware of the specific regulations of their practice contexts regarding what may be disclosed in different types of documents.

5. Is cutaneous amebiasis contagious from person to person?

Direct transmission of cutaneous amebiasis from person to person is extremely rare. Infection by E. histolytica is typically acquired through the fecal-oral route, by ingestion of cysts in contaminated water or food. Cutaneous amebiasis generally represents extension of intestinal or visceral infection in the same individual, not a transmissible primary cutaneous infection. Theoretically, direct contact with secretions from cutaneous lesions containing viable trophozoites could transmit infection if there were inoculation into mucous membranes or damaged skin of another person, but this is extremely uncommon in clinical practice. Standard precautions for hygiene and infection control are sufficient in managing patients with cutaneous amebiasis. The focus of prevention should be on basic sanitation measures, adequate treatment of water and food, and personal hygiene to prevent primary intestinal infection.

6. Do patients with cutaneous amebiasis always have intestinal symptoms?

Not always. Although most cases of cutaneous amebiasis occur in the context of current or recent intestinal amebiasis, some patients may not present with evident gastrointestinal symptoms at the time of cutaneous lesion diagnosis. This may occur because intestinal symptoms were mild and went unnoticed, because amebic colitis was asymptomatic (which can occur in some individuals), or because there was a time interval between intestinal infection and development of the cutaneous manifestation. In cases of hematogenous dissemination (very rare), the cutaneous lesion may appear without prominent intestinal symptoms. Therefore, the absence of a history of diarrhea or other gastrointestinal symptoms does not exclude the diagnosis of cutaneous amebiasis, and confirmation should be based on specific laboratory findings.

7. Is there risk of recurrence after complete treatment?

The risk of recurrence after complete and adequate treatment is low. The key to preventing recurrences is completing both the tissue phase and the luminal phase of treatment. The tissue amebicide (metronidazole or tinidazole) eliminates invasive trophozoites in tissues, but may not eradicate cysts in the intestinal lumen. The subsequent luminal agent (paromomycin, iodoquinol, or diloxanide furoate) eliminates these cysts, preventing endogenous reinfection. Recurrences generally occur when treatment is incomplete or when there is reexposure to the parasite through contaminated water or food. Patients should be counseled about preventive measures, including proper hygiene, treatment of drinking water, and food safety. In endemic areas with poor sanitary conditions, the risk of reinfection remains, but this represents a new infection, not a recurrence of the original treated infection.

8. What are the main risk factors for developing cutaneous amebiasis?

The main risk factors include: residence or travel to endemic areas with inadequate sanitation; history of untreated or inadequately treated intestinal amebiasis; immunosuppression (HIV/AIDS, use of corticosteroids or other immunosuppressants, chemotherapy); malnutrition; abdominal or perineal surgical procedures in patients with intestinal amebiasis; and conditions that compromise skin integrity in the perianal region (fissures, fistulas, complicated hemorrhoids). Workers in contact with sewage or fecal material may have increased risk of initial exposure to E. histolytica. Sexual practices involving oroanal contact have been identified as a risk factor in some studies. Recognizing these risk factors helps in early diagnostic suspicion and implementation of appropriate preventive measures.

Conclusion

Cutaneous amebiasis, coded as 1A36.12 in ICD-11, represents a rare but clinically significant manifestation of Entamoeba histolytica infection. Precise coding of this condition is essential for appropriate medical documentation, epidemiological surveillance, communication among healthcare professionals, and proper case management.

This guide provided a comprehensive approach to recognizing when code 1A36.12 is appropriate, how to differentiate it from other conditions, and how to properly document cases. Diagnostic confirmation through specific laboratory methods, complete treatment with tissue and luminal amebicides, and appropriate clinical follow-up are fundamental for favorable outcomes.

Healthcare professionals should maintain a high index of suspicion for cutaneous amebiasis in patients with atypical cutaneous ulcers, especially in contexts of exposure to poor sanitary conditions, history of suggestive gastrointestinal symptoms, or in immunocompromised patients. A multidisciplinary approach, involving dermatologists, infectious disease specialists, and pathologists, is frequently necessary for optimal diagnosis and management.

External References

This article was prepared based on reliable scientific sources:

1. 🌍 WHO ICD-11 - Cutaneous amebiasis
2. 🔬 PubMed Research on Cutaneous amebiasis
3. 🌍 WHO Health Topics
4. 📋 CDC - Centers for Disease Control
5. 📊 Clinical Evidence: Cutaneous amebiasis
6. 📋 Ministry of Health - Brazil
7. 📊 Cochrane Systematic Reviews

References verified on 2026-02-04